Logo image of VEEA

VEEA INC (VEEA) Stock Fundamental Analysis

NASDAQ:VEEA - Nasdaq - US6934891226 - Common Stock - Currency: USD

0.5638  -0.08 (-11.91%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to VEEA. VEEA was compared to 283 industry peers in the Software industry. VEEA may be in some trouble as it scores bad on both profitability and health. VEEA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

VEEA had negative earnings in the past year.
In the past year VEEA has reported a negative cash flow from operations.
VEEA Yearly Net Income VS EBIT VS OCF VS FCFVEEA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 10M -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of VEEA (-186.08%) is worse than 94.35% of its industry peers.
Industry RankSector Rank
ROA -186.08%
ROE N/A
ROIC N/A
ROA(3y)-99.07%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VEEA Yearly ROA, ROE, ROICVEEA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

VEEA's Gross Margin of 39.91% is on the low side compared to the rest of the industry. VEEA is outperformed by 75.27% of its industry peers.
The Profit Margin and Operating Margin are not available for VEEA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VEEA Yearly Profit, Operating, Gross MarginsVEEA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -10K -20K -30K

0

2. Health

2.1 Basic Checks

VEEA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VEEA has more shares outstanding
Compared to 1 year ago, VEEA has an improved debt to assets ratio.
VEEA Yearly Shares OutstandingVEEA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
VEEA Yearly Total Debt VS Total AssetsVEEA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

VEEA has an Altman-Z score of -19.97. This is a bad value and indicates that VEEA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -19.97, VEEA is doing worse than 92.93% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.97
ROIC/WACCN/A
WACC10.63%
VEEA Yearly LT Debt VS Equity VS FCFVEEA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 0.54 indicates that VEEA may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.54, VEEA is doing worse than 88.69% of the companies in the same industry.
A Quick Ratio of 0.23 indicates that VEEA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.23, VEEA is doing worse than 95.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.23
VEEA Yearly Current Assets VS Current LiabilitesVEEA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 10M 20M 30M

0

3. Growth

3.1 Past

VEEA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -263.06%.
Looking at the last year, VEEA shows a very negative growth in Revenue. The Revenue has decreased by -98.44% in the last year.
EPS 1Y (TTM)-263.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%131.38%
Revenue 1Y (TTM)-98.44%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VEEA Yearly Revenue VS EstimatesVEEA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2M 4M 6M 8M

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VEEA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VEEA Price Earnings VS Forward Price EarningsVEEA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VEEA Per share dataVEEA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for VEEA!.
Industry RankSector Rank
Dividend Yield N/A

VEEA INC

NASDAQ:VEEA (8/18/2025, 2:04:30 PM)

0.5638

-0.08 (-11.91%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)05-21 2025-05-21
Earnings (Next)09-08 2025-09-08
Inst Owners5.18%
Inst Owner Change-7.07%
Ins Owners15.05%
Ins Owner Change0.66%
Market Cap22.84M
AnalystsN/A
Price TargetN/A
Short Float %1.17%
Short Ratio4.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 163.96
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.59
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0
BVpS-0.29
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -186.08%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.91%
FCFM N/A
ROA(3y)-99.07%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.23
Altman-Z -19.97
F-Score3
WACC10.63%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-263.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%131.38%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-98.44%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-919.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3083.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3040.41%
OCF growth 3YN/A
OCF growth 5YN/A